VIFOR-PHARMA
21.12.2021 07:02:12 CET | Business Wire | Press release
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced positive findings in the completed phase-IIIb DIAMOND trial of Veltassa® in heart failure patients with either manifest hyperkalemia or with a history of hyperkalemia while treated with renin-angiotensin aldosterone system inhibitor (RAASi) therapy. Veltassa® demonstrated a statistically significant difference versus placebo for the primary endpoint to serum potassium levels in a high risk population.
85% of the more than 1,000 patients with either high risk of hyperkalemia or active hyperkalemia were able to be optimized to guideline recommended, life-saving RAASi treatment, including mineralocorticoid receptor antagonists, with Veltassa® during the run-in phase of the study. This shows that the gap between guideline recommendations and real-world practice regarding the use of RAASi can be addressed with Veltassa® . Veltassa® was generally well tolerated and without unexpected safety findings. Vifor Pharma expects the key trial results to be presented at a major cardiology conference in H1 2022.
“We are delighted and very encouraged about the positive read-out from the DIAMOND trial for the heart failure patient community,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “RAASi therapy saves lives and delays disease progression, but unfortunately many patients with heart failure are insufficiently treated due to risk of hyperkalemia. Hyperkalemia is a serious condition associated with life-threatening consequences. These data support an effective management of chronic hyperkalemia in heart failure patients on optimal RAASi therapy with Veltassa® . We look forward to presenting the detailed data to the scientific community in the first half of 2022.”
“This trial makes a significant contribution to the growing body of evidence showing the importance to use Veltassa® to enable RAASi and ensures optimal treatment in a high-risk population”, commented Prof. Javed Butler, Principal Investigator for the DIAMOND study. “The totality of evidence from the trials with patiromer suggests the treatment to control serum potassium and preventing hyperkalemia in heart failure patients aiding longer term optimal medical therapy.”
Vifor Pharma continues to support several data generation programs with the ongoing phase-IV PLATINUM study and the CARE-HK in HF global registry to drive evidence-based care using Veltassa® in chronic kidney disease and heart failure patients.
About the DIAMOND trial
This global, multicenter, double-blind, placebo controlled study was designed to evaluate the potential role of Veltassa®
in enabling patients with, or at high risk of, hyperkalemia to remain on RAASi therapy. On recommendation of the independent study Executive Committee and due to COVID-19 impact on recruitment, the primary endpoint has been changed in June 2021 to investigate the role of Veltassa®
in controlling serum potassium, preventing hyperkalemia and maintain RAASi use in heart failure patients.
About Vifor Pharma Group
Vifor Pharma Group is a global pharmaceuticals company. It aims to become the global leader in iron deficiency, nephrology and cardio-renal therapies. The company is a partner of choice for pharmaceuticals and innovative patient-focused solutions. Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives. The company develops, manufactures and markets pharmaceutical products for precision patient care. Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care). Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
For more information, please visit viforpharma.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005646/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compvide™ Announces Strategic Collaboration with OpZira™ to Accelerate Growth and Advance the CIMED™ Platform16.7.2026 12:47:00 CEST | Press release
Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform. Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.” “Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen
Compass Pathways Announces Publication of Post-Hoc Analysis Demonstrating Distinction of COMP360 Trial Monitoring & Support from Psychotherapy16.7.2026 12:35:00 CEST | Press release
Post-hoc analysis of support methods used in an open-label Phase 2 COMP360 study showed monitoring and support provided during treatment administration sessions were minimal, non-directive and distinct from conventional conceptions of psychotherapyFindings published in the Journal of Psychopharmacology Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment administration sessions showed minimal interaction. Monitoring and support were linked by patients to presence, availability, reassurance and validation. The limited and non-directive nature of these interactions distinguishes this fo
Circus Commences Operations with Ukrainian Ground Forces16.7.2026 12:04:00 CEST | Press release
Circus SE (WKN: A2YN35 / ISIN: DE000A2YN355 / XETRA: CA1), today announces the commencement of live operations of its robotic-based troop supply technology with the 3rd Army Corps of the Ukrainian Ground Forces in the Kyiv area – marking the first ever use of autonomous meal supply systems within an active conflict environment. Ahead of deployment, Circus received regulatory certification from the State Service of Ukraine for Food Safety and Consumer Protection. This certification confirms compliance with all applicable health, quality, and safety standards required to import the company's technology into Ukraine, and clears the path for operational use at scale. Soldiers are supplied using Circus's full technology stack, comprising the hardware system, AI-controlled software, and proprietary ingredient infrastructure that underpins autonomous meal production in military environments. The deployment marks Circus's entry into the Ukrainian market and the operational commencement of the
Fourthline and Veridas Join Forces to Fight Identity Fraud with a Global Identity Platform16.7.2026 11:21:00 CEST | Press release
Founded in Europe, now with global reach: backed by European investors and bringing bank-grade European compliance standards to markets worldwide Customer Value: A streamlined, end-to-end user experience that protects identity across the entire customer lifetime and helps customers grow revenue safely and compliantly. The Expected Result:Fourthline and Veridas are joining forces to create a global bank-grade identity platform: sovereign AI, modular compliance, and proprietary anti-fraud and biometric technology across Europe, Latin America, and the US. One trusted partner for end-to-end KYC, AML, and Identity compliance. Terms of Deal: Following completion of the merger, Veridas shareholders (including BBVA) will continue as shareholders in the combination, and the transaction will be partially funded by existing Fourthline investor Finch Capital and new investors including Rabo Investments, the captive investment arm of Rabobank. Expected close is in the second half of 2026, pending c
Tax Systems Rebrands as Alphatax16.7.2026 10:00:00 CEST | Press release
New brand unveiled at Tax Tech Live 2026 as company sets out AI-powered vision to become the trusted intelligence powering modern tax Tax Systems, a global tax and accounting software provider, today announced it is rebranding as Alphatax, aligning the company with its flagship corporation tax compliance solution and marking the next stage in its evolution as an AI-first technology business. The rebrand reflects the company's ambition to redefine how tax professionals work through connected, AI-powered technology. As Alphatax, the business is bringing together compliance, data, governance and intelligence into a single platform, creating the foundations for the world’s first tax operating system: a connected environment where tax data, decisions, approvals, filings and evidence can come together. The new identity builds on the strong reputation of Alphatax, a market-leading corporation tax software trusted by tax professionals across the world. Bringing the company’s expanding portfoli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom